[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343563-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343563-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ddpcr-overcomes-the-crispr-cas13a-based-technique-for-the-detection-of-the-braf-pv600e-mutation-in-liquid-biopsies","ddPCR Overcomes the CRISPR-Cas13a-Based Technique for the Detection of the BRAF p.V600E Mutation in Liquid Biopsies","","The isolation of circulating tumoral DNA (ctDNA) from liquid biopsy samples enables detection of tumor-derived genomic aberrations, but the low ctDNA abundance necessitates highly sensitive methods for actionable mutation profiling. This study evaluates a CRISPR-Cas13a-based approach using standard genomic DNA and eight patient liquid biopsy samples, benchmarking diagnostic performance against qPCR and ddPCR for the BRAF p.V600E mutation. Although the CRISPR-Cas13a complex detected very low inputs (down to 10 pM), it showed lower specificity at low VAF, while ddPCR achieved 0.1% VAF with higher reproducibility. The findings support ddPCR as the most suitable technique for clinical diagnosis and monitoring when accurate low-frequency variant detection is required.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ddpcr-overcomes-the-crispr-cas13a-based-technique-for-the-detection-of-the-braf-pv600e-mutation-in-liquid-biopsies/343563/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ddpcr-overcomes-the-crispr-cas13a-based-technique-for-the-detection-of-the-braf-pv600e-mutation-in-liquid-biopsies/343563.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical problem does the study address?","Question",{"text":63,"@type":64},"The study targets the challenge of detecting actionable genomic mutations from liquid biopsy samples where ctDNA is scarce, requiring highly sensitive detection methods.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does CRISPR-Cas13a performance compare with qPCR and ddPCR?",{"text":68,"@type":64},"CRISPR-Cas13a could detect inputs as low as 10 pM but showed lower specificity at low variant allele frequencies. ddPCR achieved 0.1% VAF with elevated reproducibility and stronger clinical suitability.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is ddPCR considered the most suitable technique in this work?",{"text":72,"@type":64},"ddPCR provided the lowest reported detectable variant allele frequency (0.1%) with improved reproducibility, whereas the CRISPR-Cas13a base-pair specificity failed to reliably detect actionable point mutations at low VAF.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343563,1790201514,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nddPCR Overcomes the CRISPR-Cas13a-Based Technique for the Detection of the BRAF p.V600E Mutation in Liquid Biopsies  \nIrina Palacín-Aliana 1,2,3, Noemí García-Romero 4,5, Josefa Carrión-Navarro 4,5, Pilar Puig-Serra 6, Raul Torres-Ruiz 6,7, Sandra Rodríguez-Perales 6, David Viñal 8, Víctor González-Rumayor 1 and Ángel Ayuso-Sacido 4,5,9, *  \nCitation: Palacín-Aliana, I.;  \nGarcía-Romero, N.; Carrión-Navarro, J.; Puig-Serra, P.; Torres-Ruiz, R.; Rodríguez-Perales, S.; Viñal, D.; González-Rumayor, V.; Ayuso-Sacido,Á . ddPCR Overcomes the CRISPRCas13a-Based Technique for the Detection of the BRAF p.V600E Mutation in Liquid Biopsies. Int. J. Mol. Sci. 2024, 25, 10902. [https://](https://)[ ](https://)[doi.org/10.3390/ijms252010902](doi.org/10.3390/ijms252010902)  \nAcademic Editor: Bruna Scaggiante  \nReceived: 6 September 2024  \nRevised: 7 October 2024  \nAccepted: 9 October 2024  \nPublished: 10 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Atrys Health, 08025 Barcelona, Spain; [iripalacin@gmail.com](iripalacin@gmail.com) (I.P.-A.); [vgrumayor@atryshealth.com](vgrumayor@atryshealth.com) (V.G.-R.)  \n2 Fundación de Investigación HM Hospitales, HM Hospitales, 28015 Madrid, Spain  \n3 Faculty of Science, Universidad de Alcalá, 28801 Madrid, Spain  \n4 Faculty of Experimental Sciences, Universidad Francisco de Vitoria, 28223 Madrid, Spain; [noemi.garcia@ufv.es](noemi.garcia@ufv.es) (N.G.-R.); [pepa.carrion@ufv.es](pepa.carrion@ufv.es) (J.C.-N.)  \n5 Brain Tumor Laboratory, Fundación Vithas, Grupo Hospitales Vithas, 28043 Madrid, Spain  \n6 Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Molecular Cytogenetics & Genome Editing Unit, Melchor Fernández Almagro, 3, 28029 Madrid, Spain; [ppuig@cnio.es](ppuig@cnio.es) (P.P.-S.); rtorresr@cnio.es (R.T.-R.); [srodriguezp@cnio.es](srodriguezp@cnio.es) (S.R.-P.)  \n7 Centro de Investigación Energéticas Medioambientales y Tecnológicas (CIEMAT), Advanced Therapies Unit, Hematopoietic Innovative Therapies Division, Instituto de Investigación Sanitaria Fundación Jimenez Diaz (IIS-FJD, UAM), 28040 Madrid, Spain  \n8 Department of Medical Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain; [dvinallozano@gmail.com](dvinallozano@gmail.com)  \n9 Faculty of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain  \n* Correspondence: ayusosa@vithas.es; Tel.: +34-686-966-904  \nAbstract: The isolation of circulating tumoral DNA (ctDNA) present in the bloodstream brings about the opportunity to detect genomic aberrations from the tumor of origin. However, the low amounts of ctDNA present in liquid biopsy samples makes the development of highly sensitive techniques necessary to detect targetable mutations for the diagnosis, prognosis, and monitoring of cancer patients. Here, we employ standard genomic DNA (gDNA) and eight liquid biopsy samples from different cancer patients to examine the newly described CRISPR-Cas13a-based technology in the detection of the BRAF p.V600E actionable point mutation and appraise its diagnostic capacity with two PCR-based techniques: quantitative Real-Time PCR (qPCR) and droplet digital PCR (ddPCR) . Regardless of its lower specificity compared to the qPCR and ddPCR techniques, the CRISPR-Cas13aguided complex was able to detect inputs as low as 10 pM. Even though the PCR-based techniques have similar target limits of detection (LoDs), only the ddPCR achieved a 0.1% variant allele frequency (VAF) detection with elevated reproducibility, thus standing out as the most powerful and suitable tool for clinical diagnosis purposes. Our results also demonstrate how the CRISPR-Cas13a can detect low amounts of t","cbCair5FCZ6K0is9","https://ap.wps.com/l/cbCair5FCZ6K0is9","pdf",3510667,15,"English","# Abstract\n# Introduction\n## Cancer drivers and BRAF p.V600E\n## Limitations of solid biopsies and rationale for liquid biopsies","[{\"question\":\"What clinical problem does the study address?\",\"answer\":\"The study targets the challenge of detecting actionable genomic mutations from liquid biopsy samples where ctDNA is scarce, requiring highly sensitive detection methods.\"},{\"question\":\"How does CRISPR-Cas13a performance compare with qPCR and ddPCR?\",\"answer\":\"CRISPR-Cas13a could detect inputs as low as 10 pM but showed lower specificity at low variant allele frequencies. ddPCR achieved 0.1% VAF with elevated reproducibility and stronger clinical suitability.\"},{\"question\":\"Why is ddPCR considered the most suitable technique in this work?\",\"answer\":\"ddPCR provided the lowest reported detectable variant allele frequency (0.1%) with improved reproducibility, whereas the CRISPR-Cas13a base-pair specificity failed to reliably detect actionable point mutations at low VAF.\"}]","ddPCR Overcomes the CRISPR-Cas13a-Based Technique for the Detection of the BRAF p.V600E Mutation in Liquid Biopsies | PDF",1790051440,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5fc649d508b61dff0b2aa857ba05382.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f90d2bc12fbe81c97cd88bdb846158b.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2876a2d520106f0f7f278072d7325659.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d51998854e385f7323de42e53c88be4b.webp",980,1385]